Mirati Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Charles M. Baum
- Full Time Employees
- 587
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3545 Cray Court San Diego CA United States of America 92121
- IPO Date
- Jul 15, 2013
- CIK
- 0001576263
- Website
- mirati.com
- Similar Companies
- Business
- Mirati Therapeutics, Inc. (MRTX) is a targeted oncology company that develops novel small-molecule therapeutics addressing genetic and immunological drivers of cancer, including inhibitors targeting KRAS mutations and other precision oncology pathways. The company offers KRAZATI (adagrasib), an oral KRAS G12C inhibitor approved for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring KRAS G12C mutations following prior systemic therapy; sitravatinib, a spectrum-selective kinase inhibitor targeting receptor tyrosine kinases including TAM family receptors, split family receptors and RET to overcome checkpoint inhibitor resistance; MRTX1719, a synthetic lethal PRMT5 inhibitor targeting the PRMT5/methylthioadenosine (MTA) complex in MTAP-deleted tumors; MRTX0902, a selective SOS1 inhibitor enhancing efficacy with MAPK-pathway inhibitors; and MRTX1133, a KRAS G12D inhibitor. It operates primarily in the United States with a focus on commercial-stage and clinical-stage oncology products for patient populations defined by specific genetic mutations, and maintains collaboration and license agreements with BeiGene Ltd. for sitravatinib development, manufacturing and commercialization, and with Zai Lab Ltd. for adagrasib in select indications. Founded in 1995 and headquartered in San Diego, California, Mirati Therapeutics was acquired by Bristol Myers Squibb Company in January 2024 for up to $5.8 billion in an all-cash transaction, integrating its pipeline into Bristol Myers Squibb's oncology portfolio while retaining key operations in San Diego. Recent major developments include Bristol Myers Squibb's termination of MRTX1133 development in March 2025 due to suboptimal pharmacokinetics despite no safety issues, discontinuation of MRTX0902 in October 2025 as part of pipeline prioritization, and ongoing Phase 1 advancement of MRTX1719 for solid tumors with MTAP deletion, alongside KRAZATI sales integration generating $118 million in 2024.
How this insider trader nailed every single stock trade
How this insider trader nailed every single stock trade
Mirati (MRTX) Gets EU Nod for Krazati in KRAS-Mutated NSCLC
European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
Cramer names biopharma companies to watch as industry mergers start to pile up
Mirati (MRTX) Up 1.1% Since Last Earnings Report: Can It Continue?
Mirati's lung cancer drug gets EU's regulatory backing
Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure
MIRATI THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mirati Therapeutics, Inc. - MRTX
Mirati's (MRTX) Q3 Loss Narrows, Sales Miss Expectations
Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
Bristol-Myers Squibb Acquisition Of Mirati Makes Sense
Mirati Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer (NSCLC)
Cancer Biotechs Pique Buyout Interest: Recent Deals in Focus
MIRATI THERAPEUTICS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mirati Therapeutics, Inc. - MRTX
Analysts Target Biotech Name on Buyout Buzz
Bristol-Myers is spending $5.8 billion to buy Mirati Therapeutics
Bristol-Myers Squibb Buys Mirati Therapeutics to Boost Cancer Drug Portfolio
Bristol Myers Squibb to buy cancer drugmaker Mirati Therapeutics in up to $5.8B deal